Dr. Overman on the Combination of Atezolizumab and Bevacizumab in HCC

Video

In Partnership With:

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in hepatocellular carcinoma (HCC).

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in hepatocellular carcinoma (HCC).

At the 2018 ESMO Congress, phase II data were presented on the combination of atezolizumab and bevacizumab in patients with HCC. The combination demonstrated high response rates and early signals of durability. Though these were early data, Overman explains that the combination of a PD-L1 inhibitor with a VEGF inhibitor seems to show synergy.

This same combination was explored with the addition of 5-FU (5-fluorouracil) in patients with colorectal cancer (CRC), data of which were also presented at the 2018 ESMO Congress. However, the regimen showed no difference compared with 5-FU and bevacizumab in terms of response rates. As more data come to light, physicians are beginning to understand that immunotherapy is not tumor agnostic.

In July 2018, the combination was granted a breakthrough therapy designation by the FDA as first-line treatment for patients with unresectable or advanced HCC.

Related Videos
In this second episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, explain the challenges faced with preventing or detecting these cancers early and the understanding that is needed to develop effective early detection methods and move the needle forward.
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD